Despite effective retinal therapy, still millions go blind every year.
Our medical co-founders have demonstrated how to overcome this issue. Now, we scale their 2nd-opinion-approach globally - using AI.
Our medical co-founders establish one of the 1st tele-ophthalmic networks worldwide (Münster "Portal") to provide 2nd opinions on retinal therapy
Digital study protocol (eCRF) to monitor success
One of the 1st publications on improving therapy adherence + persistence (patient compliance)
Start of using AI to analyse the growing therapy data with Prof. Reiner Kurzhals
Publication of 1st results in tele-ophthalmic network (Münster "Portal") of better outcomes (s. graph) and more patients remaining in therapy compared to standard-of-care
Presentation at DOC of groundbreaking 2-year-outcomes of 3x better outcomes (s. graph) + 2x more patients remaining in therapy
German AI award for deepeye research project
Incorporation of deepeye Medical GmbH
Initial publication of AI as a 2nd opinion to support retinal therapy, supported by Novartis
Collaboration with University Eye Hospital of Munich (LMU), one of the largest EU eye clinic with a retinal AI research group
Publication together with Bayer, transferring the prognostic AI to diverse populations, imaging machines and regimens
